Lamotrigine Leads October Increases In UK
Pricewatch UK – October 2023
Four presentations of epilepsy treatment lamotrigine topped WaveData’s table of the fastest-rising prices of typical generics in the UK in October.
You may also be interested in...
Partners Fresenius Kabi and Formycon have submitted a US filing for their FYB202 ustekinumab biosimilar rival to Stelara.
Samsung Bioepis has struck a US settlement with Johnson & Johnson that will allow partner Sandoz to launch the pair’s SB17 ustekinumab biosimilar to Stelara in early 2025, assuming FDA approval.
Running until 5 December, the Big Give campaign run by UK-based charity International Health Partners is once again doubling the value of donations, this year to support its child oncology programs in Malawi and Cameroon.